Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite ... from a development and commercial perspective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback